V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryPDG Harmonisation (USP/EP/JP)
Compliance · The complete guide

PDG Harmonisation (USP/EP/JP)

In short

The collaborative effort by the world's major pharmacopoeias to create interchangeable standards for excipients and analytical methods.

3,134 words · ~15 min read
Three thick pharmacopoeia volumes side by side on a laboratory bench beside a mortar and pestle
The Pharmacopoeial Discussion Group harmonises excipient monographs and general chapters across the US, European and Japanese pharmacopoeias.
On this page
  1. 01Introduction to the Pharmacopoeial Discussion Group (PDG)
  2. 02The Three Founding Pillars and Recent Expansion
  3. 03The Scope: Excipients and General Chapters
  4. 04The 5-Stage Harmonisation Process
  5. 05Understanding 'Sign-Off' and Unharmonised Attributes
  6. 06Impact on Manufacturers: Efficiency and Compliance
  7. 07The Reality of the Pace and Limits of Harmonisation
  8. 08Strategy for Multi-Region Compliance
  9. 09Managing Multi-Pharmacopoeial Specs in V5
On this page · 9 sections
  1. 1Introduction to the Pharmacopoeial Discussion Group (PDG)
  2. 2The Three Founding Pillars and Recent Expansion
  3. 3The Scope: Excipients and General Chapters
  4. 4The 5-Stage Harmonisation Process
  5. 5Understanding 'Sign-Off' and Unharmonised Attributes
  6. 6Impact on Manufacturers: Efficiency and Compliance
  7. 7The Reality of the Pace and Limits of Harmonisation
  8. 8Strategy for Multi-Region Compliance
  9. 9Managing Multi-Pharmacopoeial Specs in V5
AI · Explain it for MY operation

How does PDG Harmonisation (USP/EP/JP) apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01Introduction to the Pharmacopoeial Discussion Group (PDG)

In the complex landscape of global pharmaceutical manufacturing, the ability to market a single drug product across multiple jurisdictions depends heavily on the consistency of raw material standards. For decades, manufacturers faced a significant hurdle: the three major global markets—the United States, Europe, and Japan—maintained distinct compendial standards for the same ingredients. A manufacturer of a tablet sold in all three regions often had to perform three separate sets of laboratory tests on a single batch of lactose or magnesium stearate to satisfy the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP).

The Pharmacopoeial Discussion Group (PDG) was formed in 1989 to address this redundancy. By bringing together the technical experts from the USP, the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, the PDG set out to 'harmonise' these standards. The goal was not to create a single 'world pharmacopoeia,' but rather to ensure that the requirements for a given excipient or general test method were sufficiently similar that a manufacturer could test against one standard and be confident that the results would be acceptable to all three regulators.

Harmonisation is a technical and diplomatic achievement. It involves reconciling different analytical traditions, instrumentation preferences, and regional regulatory mandates. While the PDG has successfully harmonised dozens of the most common excipients and critical general chapters (such as those for dissolution, disintegration, and sterility testing), the process remains ongoing, meticulous, and deliberately slow to ensure the highest levels of scientific rigor. It represents a commitment to reducing the unnecessary burden on the industry while maintaining the safety and efficacy of the global medicine supply.

02The Three Founding Pillars and Recent Expansion

For over thirty years, the PDG consisted of three core members, each representing a massive economic and regulatory bloc. Understanding the PDG requires understanding the distinct roles these organizations play in their home regions.

  • The United States Pharmacopeia (USP): A non-profit, private organization that sets standards for medicines, food ingredients, and dietary supplements. Its standards are legally enforceable by the FDA under the Federal Food, Drug, and Cosmetic Act. The USP has a long history of independent standard-setting, often leading the way in modern instrumental methods.
  • The European Pharmacopoeia (Ph. Eur.): Managed by the EDQM, a directorate of the Council of Europe. It provides a common set of standards for 39 member states, ensuring that drugs crossing borders within the European Union and beyond meet a single, high-quality benchmark. The Ph. Eur. is unique in its multinational reach and its legal status across various European countries.
  • The Japanese Pharmacopoeia (JP): Established by the Japanese Ministry of Health, Labour and Welfare (MHLW) and supported by the PMDA, the JP is the official standard for drugs in Japan. It is known for its rigorous approach to analytical precision and its careful consideration of traditional manufacturing practices.

While these three remain the 'founding' members, the PDG has recently entered a new era of expansion. The World Health Organization (WHO) has long served as an observer, ensuring that the work of the PDG aligns with the International Pharmacopoeia (Ph. Int.) used in many developing nations. This observer status allows for a two-way exchange of information, where the PDG's technical consensus informs global health standards, and the WHO's global perspective helps the PDG members understand the challenges faced by manufacturers in resource-limited settings.

In a landmark move in 2023, the Indian Pharmacopoeia Commission (IPC) joined the PDG as a full member. This expansion reflects India's status as the 'pharmacy of the world' and the critical need to integrate Indian manufacturing standards into the global framework. The addition of the IPC is expected to accelerate the harmonisation of excipients common in the generic drug industry, further streamlining global trade.

Harmonisation is not a surrender of sovereignty. Each member pharmacopoeia maintains its own legal text and publication schedule. When a monograph is harmonised, the technical content is agreed upon, but the presentation and legal context remain regional.

03The Scope: Excipients and General Chapters

The PDG does not attempt to harmonise every possible aspect of pharmaceutical quality. Instead, it focuses its resources where the impact on global trade and manufacturing efficiency is greatest: excipients and general chapters. This strategic focus ensures that the group can achieve meaningful consensus without becoming bogged down in the infinite complexity of individual drug products.

Excipient Monographs

Excipients—the inactive ingredients that make up the bulk of most dosage forms—are the primary targets for harmonisation. Because a single excipient like Microcrystalline Cellulose (MCC) can be used in thousands of different drug products, harmonising the MCC monograph provides massive cumulative savings for the industry. The PDG maintains a 'Work Programme' of excipients, prioritizing those with high volume and those where regional differences cause the most significant testing burdens. Examples of successfully harmonised excipients include lactose monohydrate, magnesium stearate, and various starches.

General Chapters

General chapters define the methods by which quality is measured. These include physical tests (disintegration, friability), chemical tests (pH, conductivity), and microbiological tests (sterility, endotoxins). Harmonising a general chapter is often more difficult than harmonising a specific excipient because the chapter affects every product that uses that method.

For example, harmonising the 'Dissolution' chapter required the USP, Ph. Eur., and JP to agree on the exact dimensions of the paddles and baskets, the rotation speeds, and the allowable tolerances for the equipment. This ensures that a dissolution test performed in a lab in Osaka yields results that are directly comparable to one performed in a lab in New Jersey, using equipment that meets the same specifications.

It is important to note that the PDG generally does not harmonise Active Pharmaceutical Ingredient (API) monographs. API monographs are highly specific to the individual drug and are often influenced by the specific manufacturing process of the innovator company. The harmonisation of API requirements is largely handled through the International Council for Harmonisation (ICH) guidelines (such as ICH Q7 for GMP), which focus on the process and quality management rather than the specific compendial specification for each individual chemical entity.

04The 5-Stage Harmonisation Process

The PDG follows a formal, transparent process to move a monograph from a regional standard to a harmonised one. This process is designed to allow for public comment and technical debate, ensuring that no region is forced to adopt a standard that compromises patient safety. Each stage requires a formal consensus among the members.

  1. Stage 1: Identification: The PDG identifies a new item for the work programme or a need to revise an existing harmonised text. One of the member pharmacopoeias is designated as the 'Lead Pharmacopoeia' for that specific item, based on their expertise or interest.
  2. Stage 2: Technical Coordination: The Lead Pharmacopoeia drafts a proposal (the 'Stage 2 draft') and circulates it to the other members. This is the period of intense laboratory work and technical negotiation where differences in analytical methods, limits, and reagents are hashed out. Multiple iterations may be required to reach a consensus draft.
  3. Stage 3: Public Inquiry: Once the PDG members agree on a draft, it is published simultaneously in the USP (Pharmacopeial Forum), the Ph. Eur. (Pharmeuropa), and the JP (JP Forum) for public comment. This stage is vital as it allows manufacturers, who must actually implement the tests, to identify any practical issues, such as the availability of specific reagents or the feasibility of new instrumental methods.
  4. Stage 4: Consensus and Sign-Off: The PDG reviews the public comments and makes necessary revisions. When all members are in agreement on the final technical text, the technical coordinators from each pharmacopoeia formally 'sign off' on the text. This is the moment when the standard is officially considered 'harmonised.'
  5. Stage 5: Implementation: Each pharmacopoeia publishes the signed-off text in its own official compendium according to its own editorial style and schedule. The implementation date—the date the standard becomes legally effective—is aligned as closely as possible across the regions to minimize confusion.

Even after sign-off (Stage 4), a manufacturer cannot claim to meet the harmonised standard until it is officially published and reaches its 'effective date' in the respective pharmacopoeias (Stage 5). This gap can sometimes last a year or more, requiring QA teams to maintain careful version control.

05Understanding 'Sign-Off' and Unharmonised Attributes

A common misconception is that a 'harmonised' monograph is 100% identical in every region. In reality, the PDG often achieves what is known as 'partial harmonisation.' To facilitate the process and prevent a stalemate, the PDG allows for certain attributes of a monograph to remain regional.

When the PDG signs off on a monograph, they produce a 'Sign-off Cover Sheet.' This document is the ultimate reference for quality professionals. It explicitly lists the degree of harmonisation achieved. These cover sheets are published by the member pharmacopoeias and are essential for any laboratory performing multi-market testing.

The cover sheet breaks down the monograph into three distinct categories:

  • Harmonised Attributes: These are the tests, methods, and acceptance criteria that are identical across all member pharmacopoeias. Testing these once satisfies the requirements for all regions. This is the 'gold standard' for efficiency.
  • Non-harmonised Attributes: These are tests that are required by one or more of the pharmacopoeias but not all. For example, the JP might maintain a specific purity test that the USP and Ph. Eur. have decided to omit. Manufacturers selling into the JP market must still perform this test.
  • Local Requirements: These are elements that are not part of the technical monograph itself but are required for regional legal compliance. This often includes instructions for labelling, storage conditions, or the specific way that a material must be named in that region's regulatory filings.
Attribute TypeDescriptionManufacturer Action
HarmonisedIdentical test method and limits.Perform once; results valid for all regions.
Non-harmonisedRequired by some, but not all.Must perform if the product is destined for that specific region.
Local RequirementLegal/administrative instructions.Address through packaging design, labelling, or Quality Agreements.

This distinction is critical for global supply chain management. A Quality Control laboratory must be careful not to assume that a 'harmonised' material is ready for global distribution without checking the regional 'non-harmonised' requirements. V5's specification management tools are designed to handle these 'delta' requirements, ensuring that a material batch is only cleared for a specific market if it meets both the common harmonised criteria and the regional-specific requirements.

06Impact on Manufacturers: Efficiency and Compliance

For a pharmaceutical manufacturer, the work of the PDG translates directly into operational efficiency. The primary benefit is the reduction of analytical redundancy. In a pre-harmonised world, a lab might have to run three different HPLC methods for the same impurity in the same excipient because the USP, Ph. Eur., and JP each specified a slightly different column type or mobile phase. With harmonisation, a single, validated HPLC method serves all markets, reducing the time, cost, and complexity of quality control.

However, harmonisation also brings a different kind of complexity: the management of 'interchangeability.' Regulators generally allow the use of a method from a different pharmacopoeia if that method has been proven to be harmonised. This means that if a manufacturer is producing a drug for the US market but their excipient supplier only provides a Certificate of Analysis (CoA) showing Ph. Eur. results, the manufacturer can accept those results provided they have verified the harmonisation status of the specific attributes.

This requires the Quality Assurance (QA) team to maintain a deep knowledge of the PDG's progress. They must monitor the status of 'General Chapter <1226>' in the USP and similar documents in the Ph. Eur. and JP that define how to bridge these standards. If a chapter is harmonised, the manufacturer can avoid the costly 'method transfer' or 'compendial verification' that would otherwise be required for an alternative method. This is especially important for contract manufacturers (CMOs) who handle hundreds of different raw materials for dozens of different clients across the globe.

"Harmonization of pharmacopoeial standards is a key enabler for the global pharmaceutical industry, facilitating the movement of medicines across borders and ensuring consistent quality for patients worldwide."

— EDQM Statement on PDG Harmonisation

07The Reality of the Pace and Limits of Harmonisation

Despite the best intentions of the PDG, the pace of harmonisation is notoriously slow. It is not uncommon for a single excipient monograph revision to take five to ten years to move from Stage 1 to Stage 5. This 'compendial lag' is a source of frustration for manufacturers who are eager to adopt modern analytical techniques—such as Rapid Microbiological Methods (RMM)—that the pharmacopoeias have not yet agreed upon at a global level.

There are several reasons for this deliberate pace, rooted in the need for absolute scientific certainty:

  • Analytical Tradition and Robustness: One pharmacopoeia may have a long history of using a specific wet-chemistry test that they believe is more robust and less prone to equipment-related variation than the modern instrumental method proposed by another. Proving equivalence takes time and extensive cross-lab validation.
  • Resource Constraints: The experts who serve on the PDG committees are often the same experts managing their own regional pharmacopoeias and responding to urgent public health crises. The workload involved in reviewing thousands of pages of technical data is immense.
  • Instrumental and Reagent Differences: Even when everyone agrees to use HPLC, differences in the availability of specific 'standard' column types or high-purity reagents across regions can lead to months of collaborative laboratory testing to ensure results are truly equivalent and reproducible.

Furthermore, some areas are intentionally left out of the harmonisation scope. Packaging materials and medical device components, while increasingly important, are not currently a primary focus of the PDG. As biological products (biologics) become more dominant, the PDG is beginning to look at 'General Chapters' relevant to biologics (such as Host Cell Protein testing), but the inherent complexity of these large molecules makes harmonisation significantly more challenging than for small-molecule excipients.

08Strategy for Multi-Region Compliance

For companies selling globally, the strategy should not be to wait for the PDG to solve all problems, but rather to build a Quality Management System (QMS) that can handle the current reality of 'partial harmonisation.' This requires a proactive approach to regulatory intelligence and vendor management.

This involves several key practices:

  1. Vendor Specification Alignment: When sourcing excipients, require suppliers to provide CoAs that reference the 'harmonised' status of the attributes. A sophisticated supplier will list the USP/Ph. Eur./JP results side-by-side and clearly flag any non-harmonised tests.
  2. Risk-Based Testing and Verification: Focus internal laboratory resources on the 'non-harmonised' attributes. If an attribute is harmonised, the risk of regional non-compliance is significantly lower, and the supplier's CoA can be more easily leveraged as part of a vendor qualification program.
  3. Regulatory Intelligence Monitoring: Assign a team to monitor the PDG work programme. Knowing that a revision to a critical excipient like 'Polysorbate 80' is in Stage 3 allows a company to prepare for changes in their internal testing protocols, equipment needs, and regulatory filings well before the new standard becomes effective.

The goal is to move toward a 'tested once, accepted everywhere' model, even if the pharmacopoeias themselves are not yet fully there. By understanding the gaps, a manufacturer can focus their compliance efforts where they matter most, avoiding unnecessary work without increasing regulatory risk or compromising on patient safety.

09Managing Multi-Pharmacopoeial Specs in V5

Managing the intersection of USP, Ph. Eur., and JP requirements manually is a recipe for error. V5 provides a structured environment for managing these complex specifications at the material master level. Instead of a single static document for a specification, V5 treats specifications as dynamic data objects that can be queried and compared across regions.

In V5, a quality engineer can define a 'Base Harmonised Spec' for an excipient, which includes all the Stage 4 sign-off attributes. Linked to this base spec are 'Regional Extensions' for the US, EU, and Japan. When a batch of material is received, the system evaluates the CoA data against the specific requirements of the markets where that batch is intended to be used or sold.

V5’s Specification Management module allows you to flag attributes as 'PDG Harmonised.' This triggers logic that accepts compendial results from any of the three major pharmacopoeias for that specific test, which helps reduce manual overrides and avoids duplicative data entry during the quality review process.

By digitizing the PDG cover sheets and integrating them into the manufacturing workflow, V5 ensures that compliance is built into the data structure itself. This prevents the common error where a batch is cleared for the European market based on a USP-only CoA that missed a non-harmonised Ph. Eur. impurity test. The system maintains the lineage of the specification, ensuring that any update to the PDG status is reflected across all relevant material records.

Frequently asked questions

Q.Does harmonisation mean the USP, Ph. Eur., and JP will become one book?+

No. The PDG's goal is technical harmonisation, not administrative or legal unification. Each pharmacopoeia will continue to publish its own compendium, maintain its own legal authority, and include regional-specific sections that are outside the scope of harmonisation. The outcome is 'interchangeability' of results, not a single global text.

Q.What is a 'Lead Pharmacopoeia' in the PDG process?+

For every item on the PDG work programme, one member pharmacopoeia is assigned the 'Lead' role. This organization is responsible for conducting the initial research, drafting the Stage 2 proposal, and coordinating the technical responses from the other members. This prevents redundant work and ensures a clear path to consensus, with the Lead Pharmacopoeia acting as the project manager for that monograph.

Q.If I test an excipient according to a harmonised USP monograph, do I still need to test for Ph. Eur. compliance?+

For the 'harmonised attributes' listed on the PDG sign-off cover sheet, the USP test is considered equivalent to the Ph. Eur. test. However, you must still verify if there are any 'non-harmonised' attributes or 'local requirements' in the Ph. Eur. that are not covered by the USP monograph. You only avoid the tests that are explicitly marked as harmonised.

Q.How does a manufacturer know which attributes are harmonised?+

The most reliable source is the PDG 'Sign-off Cover Sheet' for the specific monograph. These are published on the websites of the USP, EDQM, and PMDA. Additionally, each pharmacopoeia usually includes a 'Harmonisation' section, specific markers, or symbols within the monograph itself to indicate which parts are harmonised and which are regional.

Q.What happens if a pharmacopoeia wants to revise a harmonised monograph?+

Any member pharmacopoeia that wishes to revise a harmonised text must bring the proposal back to the PDG. The group must then follow the 5-stage process again to ensure that the harmonisation is maintained in the new version. This prevents 'de-harmonisation' that could occur if one region updated its standards without coordinating with the others.

Primary sources

  • Pharmacopoeial Discussion Group (PDG) - EDQM
  • USP - Pharmacopeial Harmonization
  • PMDA - Pharmacopoeial Discussion Group
  • ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients

Further reading

  • USP (United States Pharmacopeia)
    Learn more about the role of the USP in setting quality standards for the US market.
  • Excipient Quality Management
    Explore how excipients are regulated and the importance of IPEC-PQG guidelines.
Talk to us about PDG Harmonisation (USP/EP/JP)

Want to see how PDG Harmonisation (USP/EP/JP) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Inside V5
  • → QMS — quality records next to the work they concern.
  • → Document control — one version in force, every change signed and explained.
Regulatory anchors
  • USP General Notices
  • EP 5.8
  • JP General Information
Related terms
  • → USP <2021>/<2022>/<2023> microbial limits

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC